Developing drugs for core social and communication impairment in autism
- PMID: 18775370
- PMCID: PMC2566849
- DOI: 10.1016/j.chc.2008.06.010
Developing drugs for core social and communication impairment in autism
Abstract
There are many challenges to studying drug effects on core social and language impairment in autism. Drugs such as fenfluramine, naltrexone, and secretin do not appear to be efficacious for these core symptoms. Risperidone has led to improvement in some aspects of social relatedness when used to treat irritability in autism. More research is needed on the utility of selective serotonin reuptake inhibitors, cholinergic drugs, glutamatergic drugs, and oxytocin for core autistic symptoms.
References
-
- Lecavalier L. Behavioral and emotional problems in young people with pervasive developmental disorders: relative prevalence, effects of subject characteristics, and empirical classification. J Autism Dev Disord. 2006 Nov;36(8):1101–1114. - PubMed
-
- Aman MG, Lam KS, Van Bourgondien ME. Medication patterns in patients with autism: temporal, regional, and demographic influences. J Child Adolesc Psychopharmacol. 2005 Feb;15(1):116–126. - PubMed
-
- Bailey A, Le Couteur A, Gottesman I, et al. Autism as a strongly genetic disorder: evidence from a British twin study. Psychol Med. 1995 Jan;25(1):63–77. - PubMed
-
- Redcay E, Courchesne E. When is the brain enlarged in autism? A meta-analysis of all brain size reports. Biol Psychiatry. 2005;58(1):1–9. - PubMed
-
- Schultz RT, Chawarska K, Volkmar F. The social brain in autism: perspectives from neuropsychology and neuroimaging. In: Moldin SO, R JLR, editors. Understanding Autism: from basic neuroscience to treatment. CRC Press; Boca Raton, FL: 2006. pp. 323–348.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
